Asset
DAZUCORILANT
CORCEPT THERAPEUTICS INCORPORATED COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05407324 | phase2 | active_not_recruiting | 2022-11-15 | 2026-10-01 | Corcept Therapeutics | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis |
| NCT06928779 | phase1 | completed | 2024-10-08 | 2024-12-09 | Corcept Therapeutics | Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant |
| NCT06495944 | phase1 | completed | 2024-05-31 | 2024-08-02 | Corcept Therapeutics | Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants |
| NCT04994743 | phase1 | completed | 2021-07-13 | 2021-09-30 | Corcept Therapeutics | Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants |
FDA applications (0)
This company has no applications containing this asset.